Cognition as a target in major depression: New developments

European Neuropsychopharmacology

Volumn 25, Issue 2, 2015, Pages 231-247

  Solé, Brisa ^a   Jiménez, Esther ^a   Martinez Aran, Anabel ^a   Vieta, Eduard ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Adjunctive treatment; Cognition; Major depression; Monotherapy

Indexed keywords

ACETYLCYSTEINE; ANIRACETAM; BITOPERTIN; CYCLOSERINE; DEXTRO SERINE; DEXTROMETHORPHAN; DONEPEZIL; ERYTHROPOIETIN; GALANTAMINE; KETAMINE; LANICEMINE; LISDEXAMFETAMINE; LURASIDONE; MEMANTINE; METYRAPONE; MIFEPRISTONE; MODAFINIL; OMEGA 3 FATTY ACID; OXYTOCIN; PRAMIPEXOLE; PRASTERONE; PROPOFOL; RAPASTINEL; RILUZOLE; RIVASTIGMINE; ROPINIROLE; S ADENOSYLMETHIONINE; SCOPOLAMINE; UNINDEXED DRUG; VORTIOXETINE; ANTIDEPRESSANT AGENT; NOOTROPIC AGENT;

ARTICLE; COGNITION; COGNITIVE DEFECT; HUMAN; HUMAN CELL; LANGUAGE; LITERATURE; MAJOR DEPRESSION; MEDLINE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PUBLICATION; ANIMAL; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; ANTIDEPRESSIVE AGENTS; COGNITION; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84929597055     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.12.004     Document Type: Article

References (101)

1. Ago Y., Koda K., Takuma K., Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J. Pharmacol. Sci. 2011, 116:6-17.
2. Anaya C., Martinez A.A., yuso-Mateos J.L., Wykes T., Vieta E., Scott J. A systematic review of cognitive remediation for schizo-affective and affective disorders. J. Affect. Disord. 2012, 142:13-21.
3. Antypa N., Smelt A.H., Strengholt A., Van der Does A.J. Effects of omega-3 fatty acid supplementation on mood and emotional information processing in recovered depressed individuals. J. Psychopharmacol. 2012, 26:738-743.
4. Appleton K.M., Hayward R.C., Gunnell D., Peters T.J., Rogers P.J., Kessler D., Ness A.R. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am. J. Clin. Nutr. 2006, 84:1308-1316.
5. Appleton K.M., Rogers P.J., Ness A.R. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am. J. Clin. Nutr. 2010, 91:757-770.
6. Arnsten A.F., Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol. Psychiatry 2005, 57:1377-1384.
7. Bakermans-Kranenburg M.J., van I.J.M. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl. Psychiatry 2013, 3:e258.
8. Bartz J.A., Zaki J., Bolger N., Ochsner K.N. Social effects of oxytocin in humans: context and person matter. Trends Cogn. Sci. 2011, 15:301-309.
9. Baune B.T., Miller R., McAfoose J., Johnson M., Quirk F., Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010, 176:183-189.
10. Baune B.T., Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression-A systematic review. Psychiatry Res. 2014, 219:25-50.
11. Blier P. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder. Biol. Psychiatry 2013, 74:238-239.
12. Bonnin C.M., Gonzalez-Pinto A., Sole B., Reinares M., Gonzalez-Ortega I., Alberich S., Crespo J.M., Salamero M., Vieta E., Martinez-Aran A., Torrent C. Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. J. Affect. Disord. 2014, 160:50-54.
13. Bora E., Harrison B.J., Yucel M., Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol. Med. 2013, 43:2017-2026.
14. Burgdorf J., Zhang X.L., Nicholson K.L., Balster R.L., Leander J.D., Stanton P.K., Gross A.L., Kroes R.A., Moskal J.R. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 2013, 38:729-742.
15. Catala-Lopez F., Genova-Maleras R., Vieta E., Tabares-Seisdedos R. The increasing burden of mental and neurological disorders. Eur. Neuropsychopharmacol. 2013, 23:1337-1339.
16. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot. Essent. Fatty Acids 2006, 75:259-269.
17. DeBattista C., Lembke A., Solvason H.B., Ghebremichael R., Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J. Clin. Psychopharmacol. 2004, 24:87-90.
18. Diamond P.R., Farmery A.D., Atkinson S., Haldar J., Williams N., Cowen P.J., Geddes J.R., McShane R. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J. Psychopharmacol. 2014, 28:536-544.
19. Dias V.V., Balanza-Martinez V., Soeiro-de-Souza M.G., Moreno R.A., Figueira M.L., hado-Vieira R., Vieta E. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr. Scand. 2012, 126:315-331.
20. Dilsaver S.C. Cholinergic mechanisms in depression. Brain Res. 1986, 396:285-316.
21. Drevets W.C., Zarate C.A., Furey M.L. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol. Psychiatry 2013, 73:1156-1163.
22. Ebner N.C., Maura G.M., Macdonald K., Westberg L., Fischer H. Oxytocin and socioemotional aging: current knowledge and future trends. Front. Hum. Neurosci. 2013, 7:487.
23. Elgamal S., MacQueen G. Galantamine as an adjunctive treatment in major depression. J. Clin. Psychopharmacol. 2008, 28:357-359.
24. Ellenbogen M.A., Linnen A.M., Cardoso C., Joober R. Intranasal oxytocin impedes the ability to ignore task-irrelevant facial expressions of sadness in students with depressive symptoms. Psychoneuroendocrinology 2013, 38:387-398.
25. Ferguson J.M., Shingleton R.N. An open-label, flexible-dose study of memantine in major depressive disorder. Clin. Neuropharmacol. 2007, 30:136-144.
26. Furey M.L., Drevets W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch. Gen. Psychiatry 2006, 63:1121-1129.
27. Goeldner C., Ballard T.M., Knoflach F., Wichmann J., Gatti S., Umbricht D. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology 2013, 64:337-346.
28. Goss A.J., Kaser M., Costafreda S.G., Sahakian B.J., Fu C.H. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J. Clin. Psychiatry 2013, 74:1101-1107.
29. Guastella A.J., MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: evidence and future directions. Horm. Behav. 2012, 61:410-418.
30. Heresco-Levy U., Gelfin G., Bloch B., Levin R., Edelman S., Javitt D.C., Kremer I. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int. J. Neuropsychopharmacol. 2013, 16:501-506.
31. Herrera-Guzman I., Gudayol-Ferre E., Herrera-Guzman D., Guardia-Olmos J., Hinojosa-Calvo E., Herrera-Abarca J.E. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J. Psychiatr. Res. 2009, 43:855-863.
32. Holtzheimer P.E., Meeks T.W., Kelley M.E., Mufti M., Young R., McWhorter K., Vito N., Chismar R., Quinn S., Dey S., Byrd E.H., McDonald W.M. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int. J. Geriatr. Psychiatry 2008, 23:625-631.
33. Hudetz J.A., Pagel P.S. Neuroprotection by ketamine: a review of the experimental and clinical evidence. J. Cardiothorac. Vasc. Anesth. 2010, 24:131-142.
34. Ibrahim L., Diaz G.N., Jolkovsky L., Brutsche N., Luckenbaugh D.A., Herring W.J., Potter W.Z., Zarate C.A. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J. Clin. Psychopharmacol. 2012, 32:551-557.
35. Jaeger J., Berns S., Uzelac S., vis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006, 145:39-48.
36. Jick H., Kaye J.A., Jick S.S. Antidepressants and the risk of suicidal behaviors. J. Am. Med. Assoc. 2004, 292:338-343.
37. Johnson J.W., Kotermanski S.E. Mechanism of action of memantine. Curr. Opin. Pharmacol. 2006, 6:61-67.
38. Katona C., Hansen T., Olsen C.K. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int. Clin. Psychopharmacol. 2012, 27:215-223.
39. Kavalali E.T., Monteggia L.M. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am. J. Psychiatry 2012, 169:1150-1156.
40. Keefe R.S., McClintock S.M., Roth R.M., Doraiswamy P.M., Tiger S., Madhoo M. Cogntive effects of pharmacotherpay for major depressive disorder: a systematic review. J. Clin Psychiatry 2014.
41. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). J. Am. Med. Assoc. 2003, 289:3095-3105.
42. Kessler R.C., Crum R.M., Warner L.A., Nelson C.B., Schulenberg J., Anthony J.C. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch. Gen. Psychiatry 1997, 54:313-321.
43. Krystal A.D., Weiner R.D., Dean M.D., Lindahl V.H., Tramontozzi L.A., Falcone G., Coffey C.E. Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. J. Neuropsychiatry Clin. Neurosci. 2003, 15:27-34.
44. Krystal J.H., Petrakis I.L., Mason G., Trevisan L., D'Souza D.C. N-methyl-d-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol. Ther. 2003, 99:79-94.
45. Levkovitz Y., Alpert J.E., Brintz C.E., Mischoulon D., Papakostas G.I. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. Eur. Psychiatry 2012, 27:518-521.
46. Lin P.Y., Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J. Clin. Psychiatry 2007, 68:1056-1061.
47. Loo C.K., Katalinic N., Garfield J.B., Sainsbury K., Hadzi-Pavlovic D., Mac-Pherson R. Neuropsychological and mood effects of ketamine in electroconvulsive therapy: a randomised controlled trial. J. Affect. Disord. 2012, 142:233-240.
48. Macdonald K., MacDonald T.M., Brune M., Lamb K., Wilson M.P., Golshan S., Feifel D. Oxytocin and psychotherapy: a pilot study of its physiological, behavioral and subjective effects in males with depression. Psychoneuroendocrinology 2013, 38:2831-2843.
49. MacPherson R.D., Loo C.K. Cognitive impairment following electroconvulsive therapy-does the choice of anesthetic agent make a difference?. J. ECT 2008, 24:52-56.
50. Madhoo M., Keefe R.S., Roth R.M., Sambunaris A., Wu J., Trivedi M.H., Anderson C.S., Lasser R. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacology 2014, 39:1388-1398.
51. Mah B.L., Van Ijzendoorn M.H., Smith R., Bakermans-Kranenburg M.J. Oxytocin in postnatally depressed mothers: its influence on mood and expressed emotion. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 40:267-272.
52. Matthews J.D., Blais M., Park L., Welch C., Baity M., Murakami J., Sklarsky K., Homberger C., Fava M. The impact of galantamine on cognition and mood during electroconvulsive therapy: a pilot study. J Psychiatr Res. 2008, 42(7):526-531.
53. Matthews J.D., Siefert C.J., Blais M.A., Park L.T., Siefert C.J., Welch C.A., Dubois C.M., van Nieuwenhuizen A.O., Rooney K.O., Seabrook R.C., Durham L.E., Adams H.C., Fava M. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J. ECT 2013, 29:170-178.
54. Mausbach B.T., Harvey P.D., Goldman S.R., Jeste D.V., Patterson T.L. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr. Bull. 2007, 33:1364-1372.
55. McDaniel W.W., Sahota A.K., Vyas B.V., Laguerta N., Hategan L., Oswald J. Ketamine appears associated with better word recall than etomidate after a course of 6 electroconvulsive therapies. J. ECT 2006, 22:103-106.
56. McIntyre R.S. Using measurement strategies to identify and monitor residual symptoms. J. Clin. Psychiatry 2013, 74(Suppl. 2):S14-S18.
57. McIntyre R.S., Lophaven S., Olsen C.K. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int. J. Neuropsychopharmacol. 2014, 1-11.
58. Minzenberg M.J., Carter C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008, 33:1477-1502.
59. Mischoulon D., Fava M. Role of S-adenosyl-l-methionine in the treatment of depression: a review of the evidence. Am. J. Clin. Nutr. 2002, 76:1158S-1161S.
60. Miskowiak K.W., Favaron E., Hafizi S., Inkster B., Goodwin G.M., Cowen P.J., Harmer C.J. Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology 2010, 210:419-428.
61. Miskowiak K.W., Vinberg M., Christensen E.M., Bukh J.D., Harmer C.J., Ehrenreich H., Kessing L.V. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacology 2014, 39:1399-1408.
62. Miskowiak K.W., Vinberg M., Harmer C.J., Ehrenreich H., Kessing L.V. Erythropoietin: a candidate treatment for mood symptoms and memory dysfunction in depression. Psychopharmacology 2012, 219:687-698.
63. Muhonen L.H., Lonnqvist J., Juva K., Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J. Clin. Psychiatry 2008, 69:392-399.
64. Muller U., Steffenhagen N., Regenthal R., Bublak P. Effects of modafinil on working memory processes in humans. Psychopharmacology 2004, 177:161-169.
65. Murrough J.W., Wan L.B., Iacoviello B., Collins K.A., Solon C., Glicksberg B., Perez A.M., Mathew S.J., Charney D.S., Iosifescu D.V., Burdick K.E. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology 2014, 231(3):481-488.
66. Nunes E.V., Levin F.R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. J. Am. Med. Assoc. 2004, 291:1887-1896.
67. Papakostas G.I. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. J. Clin. Psychiatry 2009, 70(Suppl. 5):S18-S22.
68. Papakostas G.I., Mischoulon D., Shyu I., Alpert J.E., Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am. J. Psychiatry 2010, 167:942-948.
69. Pelton G.H., Harper O.L., Tabert M.H., Sackeim H.A., Scarmeas N., Roose S.P., Devanand D.P. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int. J. Geriatr. Psychiatry 2008, 23:670-676.
70. Pincus D., Kose S., Arana A., Johnson K., Morgan P.S., Borckardt J., Herbsman T., Hardaway F., George M.S., Panksepp J., Nahas Z. Inverse effects of oxytocin on attributing mental activity to others in depressed and healthy subjects: a double-blind placebo controlled FMRI study. Front. Psychiatry 2010, 1:134.
71. Posternak M.A., Young D., Sheeran T., Chelminski I., Franklin C.L., Zimmerman M. Assessing past treatment history: test-retest reliability of the Treatment Response to Antidepressant Questionnaire. J. Nerv. Ment. Dis. 2004, 192:95-102.
72. Preskorn S.H., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol. 2008, 28:631-637.
73. Rasmussen K.G., Kung S., Lapid M.I., Oesterle T.S., Geske J.R., Nuttall G.A., Oliver W.C., Abenstein J.P. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Res. 2014, 215:362-365.
74. Reynolds C.F., Butters M.A., Lopez O., Pollock B.G., Dew M.A., Mulsant B.H., Lenze E.J., Holm M., Rogers J.C., Mazumdar S., Houck P.R., Begley A., Anderson S., Karp J.F., Miller M.D., Whyte E.M., Stack J., Gildengers A., Szanto K., Bensasi S., Kaufer D.I., Kamboh M.I., Dekosky S.T. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch. Gen. Psychiatry 2011, 68:51-60.
75. Rock P.L., Roiser J.P., Riedel W.J., Blackwell A.D. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 2013, 1-12.
76. Rogers P.J., Appleton K.M., Kessler D., Peters T.J., Gunnell D., Hayward R.C., Heatherley S.V., Christian L.M., McNaughton S.A., Ness A.R. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br. J. Nutr. 2008, 99:421-431.
77. Rosa A.R., Mercade C., Sanchez-Moreno J., Sole B., Mar Bonnin C.D., Torrent C., Grande I., Sugranyes G., Popovic D., Salamero M., Kapczinski F., Vieta E., Martinez-Aran A. Validity and reliability of a rating scale on subjective cognitive deficits in bipolar disorder (COBRA). J. Affect. Disord. 2013, 150:29-36.
78. Rosa A.R., Sanchez-Moreno J., Martinez-Aran A., Salamero M., Torrent C., Reinares M., Comes M., Colom F., Van R.W., yuso-Mateos J.L., Kapczinski F., Vieta E. Validity and reliability of the Functioning Assessment Short Test (FAST) in bipolar disorder. Clin. Pract. Epidemol. Ment. Health 2007, 3:5.
79. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg A.A., Fava M., Kurian B.T., Warden D., Morris D.W., Luther J.F., Husain M.M., Cook I.A., Shelton R.C., Lesser I.M., Kornstein S.G., Wisniewski S.R. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 2011, 168:689-701.
80. Sanacora G., Smith M.A., Pathak S., Su H.L., Boeijinga P.H., McCarthy D.J., Quirk M.C. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol. Psychiatry 2014, 19(9):978-985.
81. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat. Rev. Drug Discov. 2008, 7:426-437.
82. Sani G., Serra G., Kotzalidis G.D., Romano S., Tamorri S.M., Manfredi G., Caloro M., Telesforo C.L., Caltagirone S.S., Panaccione I., Simonetti A., Demontis F., Serra G., Girardi P. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012, 26:663-690.
83. Schule C., Baghai T.C., Eser D., Rupprecht R. Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression. Expert Rev. Neurother. 2009, 9:1005-1019.
84. Shiroma P.R., Albott C.S., Johns B., Thuras P., Wels J., Lim K.O. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int. J. Neuropsychopharmacol. 2014, 1-9.
85. Siren A.L., Fasshauer T., Bartels C., Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009, 6:108-127.
86. Smith E.G., Deligiannidis K.M., Ulbricht C.M., Landolin C.S., Patel J.K., Rothschild A.J. Antidepressant augmentation using the N-methyl-d-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2013, 74:966-973.
87. Sole B., Bonnin C.M., Mayoral M., Amann B.L., Torres I., Gonzalez-Pinto A., Jimenez E., Crespo J.M., Colom F., Tabares-Seisdedos R., Reinares M., yuso-Mateos J.L., Soria S., Garcia-Portilla M.P., Ibanez A., Vieta E., Martinez-Aran A., Torrent C. Functional remediation for patients with bipolar II disorder: improvement of functioning and subsyndromal symptoms. Eur. Neuropsychopharmacol. 2014.
88. Souery D., Papakostas G.I., Trivedi M.H. Treatment-resistant depression. J. Clin. Psychiatry 2006, 67(Suppl. 6):S16-S22.
89. Stahl S.M., Grady M.M. Differences in mechanism of action between current and future antidepressants. J. Clin .Psychiatry 2003, 64(Suppl. 13):S13-S17.
90. Svendsen A.M., Kessing L.V., Munkholm K., Vinberg M., Miskowiak K.W. Is there an association between subjective and objective measures of cognitive function in patients with affective disorders?. Nord. J. Psychiatry 2012, 66:248-253.
91. Torrent C., Bonnin C.M., Martinez-Aran A., Valle J., Amann B.L., Gonzalez-Pinto A., Crespo J.M., Ibanez A., Garcia-Portilla M.P., Tabares-Seisdedos R., Arango C., Colom F., Sole B., Pacchiarotti I., Rosa A.R., yuso-Mateos J.L., Anaya C., Fernandez P., Landin-Romero R., onso-Lana S., Ortiz-Gil J., Segura B., Barbeito S., Vega P., Fernandez M., Ugarte A., Subira M., Cerrillo E., Custal N., Menchon J.M., Saiz-Ruiz J., Rodao J.M., Isella S., Alegria A., Al-Halabi S., Bobes J., Galvan G., Saiz P.A., Balanza-Martinez V., Selva G., Fuentes-Dura I., Correa P., Mayoral M., Chiclana G., Merchan-Naranjo J., Rapado-Castro M., Salamero M., Vieta E. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am. J. Psychiatry 2013, 170:852-859.
92. Trivedi M.H., Cutler A.J., Richards C., Lasser R., Geibel B.B., Gao J., Sambunaris A., Patkar A.A. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. J. Clin. Psychiatry 2013, 74:802-809.
93. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163:28-40.
94. Vieta E., Colom F. Therapeutic options in treatment-resistant depression. Ann. Med. 2011, 43:512-530.
95. Watson S., Gallagher P., Porter R.J., Smith M.S., Herron L.J., Bulmer S., Young A.H., Ferrier I.N. A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol. Psychiatry 2012, 72:943-949.
96. WHO Depression: A Global Public Healrth Concern 2012, World Health Organization, Geneva.
97. Yoosefi A., Sepehri A.S., Kargar M., Akhondzadeh S., Sadeghi M., Rafei A., Alimadadi A., Ghaeli P. Comparing effects of ketamine and thiopental administration during electroconvulsive therapy in patients with major depressive disorder: a randomized, double-blind study. J. ECT 2014, 30:15-21.
98. Young A.H., Gallagher P., Watson S., Del-Estal D., Owen B.M., Ferrier I.N. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder. Neuropsychopharmacology 2004, 29:1538-1545.
99. Zarate C.A., Mathews D., Ibrahim L., Chaves J.F., Marquardt C., Ukoh I., Jolkovsky L., Brutsche N.E., Smith M.A., Luckenbaugh D.A. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol. Psychiatry 2013, 74:257-264.
100. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
101. Zarate C.A., Singh J.B., Quiroz J.A., De J.G., Denicoff K.K., Luckenbaugh D.A., Manji H.K., Charney D.S. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am. J. Psychiatry 2006, 163:153-155.